Elisabeth is Vice President and global head of late phase development for Cardiovascular, Metabolic and Chronic Kidney Disease since 2012.
Prior to this, Elisabeth led the development of Dapagliflozin, a first-in-class diabetes drug and has also been involved in the development of several other key products/drugs.
In 2014, Elisabeth moved back to Sweden after spending seven years in the US at the AstraZeneca US R&D site. She was then appointed scientific leader for the research site at Gothenburg.
Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, and was Head of the Diabetes and Endocrinology Unit at the University Hospital, Uppsala, before joining AstraZeneca in 2002.